Hunan Jiudian Pharmaceutical overhauls governance, acquires pain management drug project

Hunan Jiudian Pharmaceutical has made extensive revisions to its corporate governance, including amendments to its Articles of Association and several key management policies, effective December 2025. These updates encompass new and revised systems for preventing appropriation of funds by controlling shareholders and related parties, insider trading information management, and investor relations. The company will no longer have a Board of Supervisors, with its functions transferred to the Audit Committee under the Board of Directors, as approved by the Board and pending shareholder approval.

The company also announced the acquisition of a small molecule analgesic drug project, YJ2301, from Suzhou Yuanju Pharmaceutical Technology for a total transfer fee not exceeding 400 million yuan, to enhance its R&D capabilities in pain management. Additionally, Hunan Jiudian Pharmaceutical received a drug registration certificate for Trimebutine Maleate Tablets (0.1g), making it the fifth domestic enterprise to pass or be deemed to have passed the consistency evaluation for generic drug quality and efficacy. This expands the company's product pipeline and contributes to optimizing its product structure.

The revisions also include updates to the External Investment Management System, Information Disclosure Management System, Internal Control System, and other critical governance documents, reflecting a commitment to enhanced compliance and operational efficiency.